Development of lupic anticoagulant during combination therapy in a patient with chronic hepatitis C.
Carmona-Soria
I
I
Jiménez-Sáenz
M
M
González-Vilches
J
J
Herreriás-Gutiérrez
J M
JM
D000998:Antiviral Agents / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000097:blood / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects; D016682:Lupus Coagulation Inhibitor / Q000378:metabolism*; D008875:Middle Aged; D010314:Partial Thromboplastin Time; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D016682:Lupus Coagulation Inhibitor; D011994:Recombinant Proteins; D012254:Ribavirin